Faculty

Malini Madhavan, M.B.B.S.

Clinical Studies

A Pilot Randomized Study of the Use of The Sentinel Device for Cerebral Protection During Atrial Fibrillation Ablation Rochester, Minn.
The purpose of this study is to compare the Sentinel® Cerebral Protection System to the standard of care (no cerebral protection) in patients undergoing atrial fibrillation (AF) catheter ablation.
Enhanced Newborn Congenital Heart Disease Screening using Artificial Intelligence-enabled Electrocardiogram (ECG) and Phonocardiogram Rochester, Minn.
The purpose of the study is to develop and validate artificial Intelligence (AI) enabled sceening tools for the early detection of congenital heart disease (CHD) in newborns. This involves developing algorithms based electrocardiogram (ECG) and phonocardiogram data, both retrospective and prospectively. The study aims to improve upon current screening methods, such as pulse-oximetry, which have limitations in detecting both critical and non-critical CHD. By leveraging AI technology, the study seeks to enhance the accuracy and accessibility of CHD screening, potentially leading to better outcomes for affected newborns.

Cardiovascular Implantable Electronic Device (CIED) Antibiotic Envelope Infection Prevention Trial (WRAP-IT) Rochester, Minn.
The purpose of this study is to evaluate the ability of the TYRX Absorbable Antibacterial Envelope to reduce major cardiovascular implantable electronic device infections through 12-months post-procedure following generator replacement, upgrade, revision, or new CRT-D implant.
Characterization of Silent Cerebral Lesions in Patients Undergoing Left Heart Ablation for Ventricular Arrhythmia and Atrial Fibrillation Rochester, Minn.
The purpose of this study is to learn about the effect of atrial fibrillation on memory and thinking. This study helps us to determine how often memory problems occur in patients with atrial fibrillation and identify factors that influence changes in memory and thinking.
Randomized Trial of Apixaban vs. Dose-adjusted Warfarin in Reducing Rate of Cognitive Function Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Non-valvular Atrial Fibrillation Patients with CHA2DS2-VaSc score =2. (ARISTA) Rochester, Minn.
The purpose of this study is to assess the decline in cognitive function using standardized neurocognitive assessment in Atrial Fibrilation patients treated with Apixaban vs Warfarin.